StockIQpro
NASDAQ:WHWK

Whitehawk Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Whitehawk Therapeutics, Inc.'s revenue fell 72.5% in fiscal 2025 to $7.1M while operating margin fell to −1601.1%, its lowest in 6 years. Free cash flow was −$98.0M, −1371.4% of revenue, and the diluted share count rose 129.0%.Summary generated from Whitehawk Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$7.1M
Revenue growth−72.5%
Revenue, 5-yr CAGR−12.6%
Gross margin89.4%
Operating margin−1601.1%
Net margin−288.3%
ROICn/a
Return on equity−21.8%
Debt / equityn/a
Free cash flow−$98.0M
FCF margin−1371.4%
Share count change+129.0%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue141524267
Operating income−111−63−72−67−114
Net income−110−61−66−64−21
Free cash flow−22−50−64−61−98

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations